Market Place
Sourcing Support
Grace Therapeutics Announces Q3 Financial Results
13 Feb 2025 //
GLOBENEWSWIRE
Grace Reports Ph 3 Strive-on Safety Result For GTx-104 In aSAH
10 Feb 2025 //
GLOBENEWSWIRE
Grace Therapeutics Announces Placement Financing of up to $30 M
10 Feb 2025 //
GLOBENEWSWIRE
Grace Therapeutics To Join January 2025 Investor Events
07 Jan 2025 //
GLOBENEWSWIRE
Grace Therapeutics to Exhibit at ASHP Conference
04 Dec 2024 //
GLOBENEWSWIRE
Grace Therapeutics Reports Q2 2025 Results & Business Update
13 Nov 2024 //
GLOBENEWSWIRE
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.
25 Oct 2024 //
GLOBENEWSWIRE
Acasti Completes Enrollment In GTX-104 Phase 3 STRIVE-ON
25 Sep 2024 //
GLOBENEWSWIRE
Acasti to Present at the Life Sciences Investor Forum
12 Sep 2024 //
GLOBENEWSWIRE
Acasti To Participate In H.C. Wainwright Investment Conference
05 Sep 2024 //
GLOBENEWSWIRE
Acasti Reports Q1 2025 Results And Provides Business Update
09 Aug 2024 //
GLOBENEWSWIRE
Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 Trial
27 Jun 2024 //
GLOBENEWSWIRE
Acasti Announces Year-End 2024 Financial Results and Business Update
21 Jun 2024 //
GLOBENEWSWIRE
Acasti Pharma to Attend BIO International Convention 2024
28 May 2024 //
GLOBENEWSWIRE
Acasti Announces Third Fiscal Quarter 2024 Financial Results Highlights
12 Feb 2024 //
GLOBENEWSWIRE
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial
01 Feb 2024 //
GLOBENEWSWIRE
Acasti to Participate in San Francisco Investor Conferences in January 2024
13 Dec 2023 //
GLOBENEWSWIRE
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
13 Nov 2023 //
GLOBENEWSWIRE
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
23 Oct 2023 //
GLOBENEWSWIRE
Acasti Pharma to Host KOL Event on GTX-104
04 Oct 2023 //
GLOBENEWSWIRE
Acasti Announces $7.5 Million Private Placement Equity Financing
26 Sep 2023 //
GLOBENEWSWIRE
Acasti Announces First Quarter 2024 Financial Results and Business Highlights
11 Aug 2023 //
GLOBENEWSWIRE
Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Meeting
09 Aug 2023 //
GLOBENEWSWIRE
Acasti Announces WuXi Clinical as CRO to Conduct Phase 3 Trial for GTX-104
10 Jul 2023 //
PR NEWSWIRE
Acasti Pharma Announces 1-for-6 Reverse Stock Split
07 Jul 2023 //
PR NEWSWIRE
Acasti Announces Alignment with FDA on GTX-104 PIII Safety Trial Protocol
05 Jul 2023 //
PR NEWSWIRE
Acasti Pharma Reports Fiscal Year 2023 Operational Results
23 Jun 2023 //
PR NEWSWIRE
After laying off most staff, Acasti insists it`s still on track
23 Jun 2023 //
FIERCE BIOTECH
Acasti Announces Appointment of New Scientific Advisory Board Members
22 Jun 2023 //
PR NEWSWIRE
Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference
17 May 2023 //
PR NEWSWIRE
Acasti Successfully Submits Pivotal GTX-104 Ph 3 Safety Study Protocol with FDA
08 May 2023 //
PR NEWSWIRE
Legend Biotech looks to raise additional $350M in stock sale; Acasti to layoffs
08 May 2023 //
ENDPTS
Acasti Announces Appointment of Prashant Kohli as CEO
04 Apr 2023 //
PR NEWSWIRE
Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104
04 Apr 2023 //
PR NEWSWIRE
Acasti Pharma Inc. Announces the Resignation of a Director
30 Mar 2023 //
PR NEWSWIRE
Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference
08 Mar 2023 //
PR NEWSWIRE
Acasti Pharma Recognizes Rare Disease Day
28 Feb 2023 //
PR NEWSWIRE
Acasti Pharma Reports Third Quarter 2023 Operational Results
14 Feb 2023 //
GLOBENEWSWIRE
Acasti Pharma to Report Third Quarter 2023 Financial Results
07 Feb 2023 //
PR NEWSWIRE
Acasti Receive Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
25 Jan 2023 //
GLOBENEWSWIRE
Acasti to Present at Lytham Partners Investor Select Conference on January 31
24 Jan 2023 //
GLOBENEWSWIRE
Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
13 Jan 2023 //
GLOBENEWSWIRE
Acasti to Host Conference on Jan 10, 2023 to Discuss Results of GTX-101, GTX-102
05 Jan 2023 //
GLOBENEWSWIRE
Acasti plots path to phase 3 for steroid spray in rare disease
04 Jan 2023 //
FIERCE BIOTECH
Acasti announces positive results from pharmacokinetic bridging study of GTX-102
30 Dec 2022 //
PHARMABIZ
Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome
22 Dec 2022 //
GLOBENEWSWIRE
Acasti Pharma to Report 2nd Q 2023 Financial Results on Monday, Nov14, 2022
07 Nov 2022 //
GLOBENEWSWIRE
Acasti Announces Court Dismissal of Stockholder Litigation
30 Sep 2022 //
GLOBENEWSWIRE
Acasti Announces Voting Results from 2022 Annual and Special Meeting
29 Sep 2022 //
GLOBENEWSWIRE
Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor
14 Sep 2022 //
GLOBENEWSWIRE
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102
13 Sep 2022 //
GLOBENEWSWIRE
Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global
12 Sep 2022 //
GLOBENEWSWIRE
Acasti Pharma to Report First Quarter 2023 Financial Results
02 Aug 2022 //
GLOBENEWSWIRE
Acasti Pharma Initiates Pharmacokinetic Study for GTX-101
27 Jul 2022 //
GLOBENEWSWIRE
Acasti Pharma Announces Annual Grants of Performance Stock Options
22 Jun 2022 //
GLOBENEWSWIRE
Acasti Pharma Schedules Fiscal Year 2022 Business Update Conference Call
16 Jun 2022 //
GLOBENEWSWIRE
Acasti Pharma Announces Issuance of Additional Patents for GTX-104 and GTX-101
14 Jun 2022 //
GLOBENEWSWIRE
Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations
23 May 2022 //
PRNEWSWIRE
Acasti Pharma Announces Positive Results for PK Bridging Study
18 May 2022 //
GLOBENEWSWIRE
Acasti Pharma Appoints Michael L. Derby to its Board of Directors
25 Mar 2022 //
GLOBENEWSWIRE
